A network of molecular chaperones is known to bind proteins ('clients') and balance their folding, function and turnover. However, it is often unclear which chaperones are critical for selective recognition of individual clients. It is also not clear why these key chaperones might fail in protein-aggregation diseases. Here, we utilized human microtubule-associated protein tau (MAPT or tau) as a model client to survey interactions between ~30 purified chaperones and ~20 disease-associated tau variants (~600 combinations). From this large-scale analysis, we identified human DnaJA2 as an unexpected, but potent, inhibitor of tau aggregation. DnaJA2 levels were correlated with tau pathology in human brains, supporting the idea that it is an important regulator of tau homeostasis. Of note, we found that some disease-associated tau variants were relatively immune to interactions with chaperones, suggesting a model in which avoiding physical recognition by chaperone networks may contribute to disease.
T he chaperone network is composed of 'core' chaperones, such as heat shock protein 70 (Hsp70) and heat shock protein 90 (Hsp90), that utilize nucleotide hydrolysis to power reversible interactions with client proteins 1 . These core chaperones are further assisted by co-chaperones that help decide which clients should be bound and whether they should be folded, trafficked or degraded. Together, the entire human chaperone and co-chaperone network is composed of ~332 gene products (i.e., the 'chaperome') 2 . However, the individual components of the human chaperone network do not act in isolation; rather, they are known to engage in widespread protein-protein interactions among themselves and with clients 3, 4 . Moreover, this chaperone network is part of a broader cellular system, including translation control and the stress responses, that work together to maintain protein homeostasis (i.e., proteostasis) 1, [5] [6] [7] .
Still, this robust, conserved system can fail. For example, a shared hallmark of neurodegenerative diseases is the aberrant misfolding and aggregation of proteins 8 . Often, the pathology of these diseases is dominated by the aggregation of a single protein in the form of large, fibrillary deposits. Why does the normal proteostasis system fail in these cases? Several studies have found that levels of many chaperones and co-chaperones are reduced during aging 2, 9, 10 , which likely diminishes the overall cellular ability to maintain proteostasis. In further support of this idea, activation of longevity pathways in worms enhances chaperone expression and limits aggregation of amyloid-β and polyglutamine (polyQ) proteins 9, 10 .
This general paradigm is compelling, but it does not directly explain why specific proteins can sometimes circumvent the chaperone network. For example, missense mutation P301L in MAPT (tau) gives rise to the progressive, lethal neurodegenerative disease frontotemporal dementia with parkinsonism linked to chromosome 17 . Why does the chaperone network fail to effectively 'handle' P301L tau? We hypothesized that individual mutant proteins may sometimes evade molecular recognition by specific components of the chaperone network. Consistent with this evasion model, genetic screens have shown that overexpression of certain core chaperones, such as Hsp70s, restores protection from aggregation of polyQ proteins 11 and P301L tau 12, 13 . However, Hsp70s are rather promiscuous factors; the co-chaperones that might underlie selective, molecular recognition of tau and its variants have been less clear. This gap is understandable because partially redundant functions of co-chaperones often make large-scale genetic screens for discovering them more challenging 14 , and their direct interactions with clients are often exceptionally weak, which makes proteomics difficult.
In this study, we set out to identify chaperones and co-chaperones (from now on referred to collectively as chaperones) that directly bind to tau. We chose tau for this effort because accumulation of aggregated tau is associated with more than a dozen neurodegenerative disorders, including FTDP-17, mild cognitive impairment (MCI) and Alzheimer's disease (AD) 15 . Moreover, tau is an intrinsically disordered protein (IDP), which removes the potential complication of controlling for folding-unfolding transitions. Finally, tau is an established chaperone client, and individual chaperone interactions (i.e., positive controls) have been reported [16] [17] [18] . On the basis of these criteria, we established a series of complementary in vitro and cellular screening paradigms to identify the subset of chaperones that might bind tau and prevent its aggregation. In this effort, we studied the interactions of ~30 major chaperones with ~20 disease-associated variants of tau to understand why or how mutations and post-translational modifications (PTMs) might influence chaperone activities. From these screens, we found that the chaperone DnaJA2 is a strong inhibitor of tau aggregation and that it is active against a relatively broad number of tau variants. Furthermore, in patients with MCI and AD, we found a striking upregulation of DNAJA2 that was specific to neurons positive for markers for tau and amyloid pathology. This work showcases how a large-scale, biochemical approach to map direct interactions of clients with chaperones might complement other methods, such as genomics or proteomics, to reveal important recognition events.
Results
Select chaperones modulate tau aggregation kinetics. To date, only a limited number of chaperones (Hsc70, Hsp27 and FKBP51) have been examined in isolation for their abilities to modulate the aggregation of tau 12, 19, 20 . We set out to expand this dataset by comparative analysis of > 30 chaperones for their effects on tau aggregation kinetics. Tau is subject to splicing to produce multiple isoforms 16 .
These splice isoforms include a variable number of N-terminal repeats (0 N-2 N), a polyproline region and either three or four microtubule-binding repeats (MBRs; R1-R4) ( Fig. 1a ). An important feature of the MBRs is the presence of two aggregation motifs termed PHF6* (275-VQIINK-280) and PHF6 (306-VQIVYK-311), which are required for aggregation [21] [22] [23] . Tau aggregation is typically measured using Thioflavin T (ThT), a dye that binds β -sheets. For our studies, we miniaturized the ThT assay for use in 384-well plate format to: (i) facilitate a greater number of replicates and (ii) test multiple concentrations of each chaperone. To validate this platform, we first titrated a major constitutively expressed member of the Hsp70 family, heat shock cognate 70 (Hsc70 or HSPA8), into solutions of purified 0N4R wild-type tau (tau WT ) and measured the kinetics of aggregation after the addition of the commonly used accelerant heparin. We selected 0N4R tau for these studies because it is a major splice isoform in adult brain and has relatively rapid aggregation kinetics. Consistent with previous reports 20 , we found that purified Hsc70 increased the lag time and suppressed the elongation rate of tau aggregation reactions ( Fig. 1a and Supplementary is plotted in a heatmap with gray and orange representing observed lag times lower or higher than theoretical lag times, respectively. c, Addition of chaperones to tau aggregation assay post induction reveals multiple mechanisms of chaperone activity. Graph depicts effect of DnaJA2 addition to tau reaction mixture (1:1 ratio) at the indicated time points (arrows) during the aggregation process (arrows and corresponding curves are denoted by color). Data shown are mean ± s.e.m. of three technical replicates. Heatmap displays effect of chaperone addition at time points relative to aggregation induction on lag time parameter analyzed as described in Fig. 1d . For time point at which chaperone was added following the lag phase (+ 55 min, purple arrow), the representative bar graph plots the slope for the each aggregation curve relative to tau-alone controls (mean ± s.e.m. of three technical replicates). Fig. 1a ). In contrast, a negative-control construct of Hsc70 encompassing only the nucleotide-binding domain (Hsc70 NBD ) had relatively little effect on aggregation kinetic parameters. Next, we purified 18 variants of 0N4R tau to test in this format. These variants included disease-associated mutations (P301L, A152T and Δ K280) and mimics of disease-associated phosphorylation (T153E, T231E, S356E, S396E and S404E), acetylation (K174Q, K280Q and K281Q) and caspase-cleaved fragments (D25 and D421) ( Fig. 1b and Supplementary Table 1 ). The collection also included variants in which the individual aggregation motifs were disrupted (the natural 0N3R tau isoform and a 0N4R Δ 308/309 construct), variants with mutations in known proline isomerization motifs (P232A and T/P231E/A) as well as the widely studied synthetic tau construct K18, which includes the four MBRs. It is known that some of these modifications either accelerate or slow tau aggregation kinetics in vitro 21, 23 , so we first characterized the kinetics of each variant using the miniaturized ThT assay. Most of the 0N4R tau variants had lag times ( Fig. 1c ) and elongation rates ( Supplementary Fig. 1b ) similar to those of 0N4R tau WT , with the exception of the disease-associated mutants Δ K280 and P301L, which aggregated significantly faster. As expected, the tau variants WT 0N3R tau and Δ 308/309, which lack the PHF6 motif, had 5-to 10-fold longer lag phases and ~2-fold slower elongation rates. These baseline studies allowed us to normalize subsequent results to the intrinsic aggregation propensity of each variant.
Each tau variant was then tested against a purified human chaperone collection. The collection contained major members of the Hsp70 and small heat shock protein (sHsp) chaperone systems. The throughput of the ThT platform also allowed us to test additional chaperones previously linked to tauopathy, including clusterin, α B-crystallin, FKBP12 and Pin1 (refs [24] [25] [26] [27] ), as well as chaperones known to have roles in other protein-misfolding diseases, such as Hsp60 and HIP 28, 29 . In addition, we assayed a select number of anti-aggregation chaperones from other organisms, including yeast Hsp104 (ref. 30 ) and several newly discovered chaperones from Escherichia coli and Saccharomyces cerevisae 31, 32 . For each experiment, the purified chaperone was incubated with tau (10 µ M) prior to the addition of heparin. Additionally, each chaperone was tested Fig. 1a ). Location of chaperone-binding peptides from the peptide array experiments are indicated by diamonds and aligned with position in the 2N4R sequence. The binding profiles on tau for selected chaperones as probed by NMR (indicated by an asterisk (*)) were measured by titration of chaperones into 1 H 15 N 2N4R tau. Changes in the NMR intensity ratios (1 -I/I 0 ) for individual peaks derived from HSQC spectra (I, chaperone present; I 0 , tau alone) are plotted, aligned with their position in the 2N4R tau sequence. Chaperones/tau molar ratios assayed are indicated in parentheses. b, Tau binding profiles of a subset of anti-aggregation chaperones identified in the screen as probed by NMR of 15 N-K18 tau (2:1 molar ratio of chaperone/tau). Changes in NMR intensity ratios I/I 0 plotted as described in a). Two binding regions (1 and 2, boxed by dashed lines with corresponding amino acid sequences) were identified and regions overlap with the PHF6* and PHF6 motifs (underlined).
in triplicate at three concentrations within the range of 2.5-20 µ M to probe whether effects on aggregation were reproducible and dose dependent. Replicates of the screen demonstrated good correlation and day-to-day reproducibility ( Supplementary Fig. 1c,d ), giving us confidence in the results. In addition, the negative control (Hsc70 NBD ) was inactive ( Fig. 1d ), except for some modest, nonspecific activity against the slowly aggregating 0N3R and Δ 308/309 variants. Incubation of ~30 chaperones with ~20 tau variants revealed a fascinating pattern of effects on tau lag time ( Fig. 1d ) and elongation rate ( Supplementary Fig. 2a ). For clarity, the effects at 1:1 stoichiometry (tau/chaperone) are shown, but similar results, albeit of lower magnitude, were seen at reduced concentrations ( Supplementary  Fig. 2b ). The first striking observation was that a subset of chaperones, including Hsc70, DnaJA2, Hsp60, clusterin and Hsp104, were the most potent suppressors of tau aggregation. Interestingly, these chaperones share little similarity in terms of their chaperone families and their structures. Despite these differences, some of them are known to have anti-aggregation activity against other clients 31, 33, 34 or function as protein disaggregases 35 . The exceptions were Hsp60 and DnaJA2, which had not previously been linked to aggregation or tau biology. DnaJA2 is closely related to another J-protein member, DnaJA1. DnaJA1 could not be tested using the screen conditions, owing to issues with solubility; however, a modified tau aggregation assay showed that DnaJA1 was also able to inhibit 0N4R tau WT aggregation ( Supplementary Fig. 2c ). A construct of the conserved J domain, taken from E. coli DnaJ, had minimal effects on tau aggregation for most of the tau variants in the screen (Fig. 1d ), consistent with the idea that substrate binding is often independent of the J domain in this family of co-chaperones.
Another striking observation from this analysis was that certain tau variants, such as P301L, A152T, Δ K280, D25 and D421, were relatively resistant to even the most potent chaperones ( Fig. 1d and Supplementary Fig. 2d ). To extend this observation, we tested several hit chaperones against additional disease-associated mutations (Fig. 1f ). Consistent with the original observations, the aggregation of N279K and P301S mutants was also relatively resistant to chaperone protection when compared to that of 0N4R tau WT . This result suggests that some tau variants might partially, but broadly, circumvent the anti-aggregation activities of chaperones. It is also worth noting that the tau variants lacking one aggregation motif (0N3R and Δ 308/309) were protected by a wider range of chaperones . Unfractionated 0N4R tau WT fibrils made in the presence of the indicated chaperones were transfected, and the percentage of cells seeded were plotted. Data are mean ± s.d. of three technical replicates; data are representative of three independent experiments. c, Significant reduction in seeding phenotype observed for fibrils formed in the presence of DnaJA2. Unfractionated WT, P301L and A152T 0N4R tau fibrils formed in the presence or absence of the indicated chaperones were transfected into Clone 1 cells (60 η g tau), and the percentages of cells seeded were compared (mean ± s.e.m. of three independent experiments). Groups with > 20% reduction compared to the no-chaperone control group are shaded in green. One-way ANOVA with a post-hoc Dunnett's test, *P = 0.039, **P = 0.002, ***P = 0.0001.
( Fig. 1d ). It is known that an imbalance in the ratio of 4 R tau versus 3R tau is linked to some tauopathies 36 . Our results suggest that the switch toward 4R isoforms may make tau aggregation more resistant to chaperones. One unexpected result from this analysis was the identification of chaperones that only suppressed the aggregation of a few tau variants. For example, the small HSPs (Hsp22, Hsp27 and α B-crystallin) delayed aggregation of several tau phosphomimetics, such as S356E, but not the others. Another unexpected result was the difference in activity between the two closely related Hsp70 family members Hsc70 (HSPA8) and Hsp72 (HSPA1A). Overall, Hsc70 was a much better anti-aggregation chaperone, even though it is 94% identical to Hsp72, and both Hsc70 and Hsp72 bind to tau with similar affinities 37 . We generated analogous constructs of the isolated Hsc70 and Hsp72 substrate-binding domain (SBD) consisting of the β -sheet substrate-binding cleft and the first two α -helices of the lid (amino acids 394-540). At the highest concentrations tested (20 µ M), Hsc70 SBD and Hsp72 SBD delayed the aggregation of 0N4R tau WT to the same degree as their corresponding full-length proteins. These results suggest that the reduced anti-aggregation activity of Hsp72 can probably be attributed to the relatively few residues that differ between Hsc70 and Hsp72 in the SBD. Future studies exploring the isolated SBDs may help to shed light on the differential actions of Hsc70 and Hsp72 on tau homeostasis observed previously 37, 38 .
Finally, we were surprised to identify chaperones that promoted aggregation. For example, FKBP12 had no effect on the aggregation of 0N4R tau WT , but it promoted aggregation of the acetylation mimetic K280Q. These results support a model where, in some contexts, individual chaperones might facilitate tau pathology 19 .
Some chaperones suppress lag time, others inhibit elongation rate. While we initially focused on the effects of chaperones on lag time, our screen captured other valuable data regarding the effects on elongation rates. Studies on amyloid-β (Aβ ) have been informative in elucidating the microscopic processes occurring during different phases of an amyloid aggregation reaction 39 . From this work, stages such as primary nucleation, secondary nucleation and elongation of fibril ends all seem to contribute to the reaction. Although a parallel study on tau aggregation has not yet been reported, we hypothesized that differential effects of individual chaperones in lag time and elongation rate might be suggestive of the stage at which the chaperone was acting 40 . When profiling chaperones for their effects on aggregation kinetics across 0N4R tau variants, we observed that the chaperones Hsc70, Hsp60 and clusterin greatly slowed both lag time and elongation rate ( Fig. 2a ). However, DnaJA2 and Hsp104 were less active against tau elongation (relative to their effects on lag time), whereas Hsp27 and α B-crystallin were considerably more potent on the elongation step. These unique signatures suggested that individual chaperones might suppress only a subset of microscopic processes in the aggregation reaction. Thus, we reasoned that combining chaperones with distinct activity profiles could lead to synergistic effects. To test this idea, we assayed select, pairwise combinations of chaperones (1:1 ratio) for their effects on tau lag-time kinetics. In this analysis, we asked whether the effects on lag time when two chaperones were present (5 μ M each) would be greater than the sum of the effect observed for each chaperone when tested alone (5 μ M). In general, we found that combining two chaperones led to antagonistic, not synergistic, effects on anti-aggregation activity (Fig. 2b) . For example, combining Hsp72 with DnaJA2 or Hsp60 led to lower-than-predicted increases in lag time. This result might occur when chaperones compete for the same tau binding sites (as discussed below). Interestingly, a small subset of combinations showed synergistic activity, including DnaJA2 with Hsp22 or α B-crystallin, thus suggesting that these chaperones act by cooperative mechanisms. Next, we probed whether any of the chaperones could still suppress tau aggregation once the reaction had already been initiated, and added individual chaperones at 0, 25 or 55 min post induction. We found that delaying the addition of chaperone until 25 min into the aggregation reaction (during the lag time) still extended lag times (Fig. 2c ). However, we noticed that the magnitude of the effect was smaller when compared to addition at time zero or under screen conditions (i.e., addition of chaperone at -30 min). Delaying the addition of the chaperone until 55 min into the aggregation reaction (at the beginning of the elongation phase) largely abolished anti-aggregation activity of chaperones ( Fig. 2c) . Only DnaJA2 was able to significantly decrease the rate of aggregation under these conditions. Surprisingly, several chaperones, such as α B-crystallin, Hsp27 and clusterin, enhanced aggregation rates when added postlag phase, despite having the opposite effect when added under the screening conditions. Thus, it seems likely that chaperones can affect multiple processes in the tau aggregation pathway 40 .
One trivial reason for DnaJA2's anti-aggregation properties might be that it binds to the accelerant heparin. To test this possibility, we induced tau aggregation with an unrelated accelerant, arachidonic acid, and found that DnaJA2 retained its ability to suppress aggregation ( Supplementary Fig. 3a ). Moreover, although DnaJA2 had some, weak affinity (~2 µ M) for heparin in vitro ( Supplementary Fig. 2b ), increasing heparin levels did not abolish DnaJA2's anti-aggregation activity ( Supplementary Fig. 2c ).
Finally, we tested whether chaperones could disassemble mature fibrils (incubated > 20 h), as measured by a decrease in ThT signal. The Bukau group pioneered studies of chaperone complexes that have disaggregase activity on α -synuclein amyloids 41 . However, we found that none of the chaperones by themselves were able to reverse aggregation of 0N4R tau WT fibrils (data not shown). This result is not surprising, as the Bukau group showed that only combinations of chaperones, plus ATP, creates disaggregase activity 41 .
We have not yet identified the combination of chaperones and ATP that might act as a putative disaggregase for tau fibrils.
Chaperones bind to hotspots within the tau polypeptide. Our screen results prompted us to ask where chaperones might bind on tau. Specifically, we wondered which chaperones might bind directly to the PHF6 and PHF6* regions in the MBRs that are known to be required for tau aggregation. Previous studies have mapped where one or two chaperones bind to individual clients in vitro [42] [43] [44] [45] , but little is known about client recognition in a broader context. Peptide arrays have previously been used to map the binding sites of Hsp70s and Hsp90α on tau, and these interaction sites have been confirmed and extended by NMR spectroscopy 37, 44 . Inspired by these approaches, we mapped the binding sites on tau for our broader collection of chaperones. Briefly, a tau peptide array was generated with 15-mer peptides in four amino acid steps that covered the longest adult isoform of tau, 2N4R. We then prepared a set of His-tagged purified chaperones from the aggregation screen that were compatible with the solubility and tagging requirements of the platform. The binding of the His-tagged chaperones (10 µ M) was measured with fluorescently labeled anti-His antibodies. After removing false positives that bound anti-His antibody and/or Hsp70 NBD , we annotated true binding sites as regions composed of at least two contiguous 15-mer peptides ( Fig. 3a and Methods). We found that the previously assayed chaperones Hsp72 and Hsp90α bound sites overlapping both aggregation motifs PHF6* (aa 275-280) and PHF6 (aa 3-311) and near the polyproline-R1 boundary (aa 220-242) ( Supplementary Fig. 4a,b) , as expected 17 . Strikingly, we found that a number of other chaperones, including DnaJA1, DnaJA2, Hsp27 and FKBP51 also bound peptides in or around PHF6* and PHF6 (Fig. 3a) . We also noted that there were additional high-frequency chaperone-binding sites in the polyproline region (aa 220-242) and the N terminus (aa 5-23). These regions were also interesting because they correspond to multiple AD-associated phosphorylation sites 46 , a known Pro232 isomerization site 47 and an N-terminal region previously linked to tauopathy 48 . The peptides that bound to multiple chaperone families shared no overall similarity in characteristics such as charge, pI, aliphatic index or hydrophobicity (Supplementary Table 2 ), consistent with the relatively broad binding properties expected from these different structural classes.
Next, we carried out NMR studies on Hsp72, Hsp90, DnaJA2, Hsp27 and DnaJB4 by titrating them into solutions of 15 N-labeled WT 2N4R tau (Fig. 3a) . This experiment was important because peptide arrays cannot mirror the broader context of surrounding regions in polypeptides. Despite this complication, we found that the location of the interactions, as measured by NMR, generally supported the peptide array results. Specifically, Hsp72, Hsp90 and DnaJA2 seemed to bind regions that spanned the polyproline and MBRs (R1-R4), in alignment with previous NMR studies when available 37, 44 . However, compared to the peptide array, the NMRbased study also picked up broader footprints for Hsp72, Hsp90 and DnaJA2, which often encompassed the R3 region containing the PHF6 motif. Interestingly, no binding was observed for Hsp27, suggesting that it may modulate tau aggregation through recognition of non-monomeric forms of the protein.
To further explore the interaction of anti-aggregation chaperones with the PHF6 and PHF6* regions of tau, we carried out further NMR studies. Specifically, we titrated Hsc70, DnaJA2, clusterin and Hsp60 into solutions of 15 N-labeled WT K18 tau (Fig. 3b ). Owing to the higher resolution of this construct, we observed more discrete binding footprints. Specifically, we found that Hsc70, DnaJA2, clusterin, and Hsp60 bound to the region overlapping the PHF6 motif, along with weaker additional binding to the PHF6* region. Thus, a major mechanism of anti-aggregation activity seems to be the direct binding to tau in the aggregation-prone sequences.
A subset of chaperones suppresses formation of tau 'seeds' . Recent studies have demonstrated that tau aggregates can have prion-like activity, including the ability to induce aggregation of soluble tau when introduced to cells 49, 50 . Indeed, propagation of aggregates may be a potential mechanism for disease progression in a variety of neurodegenerative diseases 51 . Because we found that several chaperones slowed tau aggregation, we wondered whether this activity would suppress prion-like character. In support of this idea, centrifugation (100,000 g) of the tau samples co-incubated with chaperones showed that some, such as Hsc70, Hsp72 and DnaJA2, increased tau solubility ( Supplementary Fig. 5a,b ). However, even small, soluble tau species have been determined to be capable of nucleating aggregation, so we did not consider the ability to block overall aggregation a sign of anti-prion-like activity 52 . Accordingly, we used a 'clone 1' cell line developed in the Diamond laboratory, in which K18 tau is stably expressed as a fusion to yellow fluorescent protein (K18-YFP) 53 . In this model, the K18-YFP is distributed evenly in the cytoplasm but forms fluorescent puncta upon transfection with aggregated tau from patient brain or recombinant sources (Fig. 4a) . Importantly, tau seeds can be titrated into this system, and the number of cells with puncta can be quantified (Fig. 4b) . As a control, we first made sure that none of the individual chaperones reduced the number of puncta when added to preformed fibrils ( Supplementary  Fig. 5c ). This result suggested that the chaperones themselves did not reduce seeding when added exogenously.
Next, to see whether chaperones could suppress seeding activity, we transfected clone 1 cells with unfractionated 0N4R tau WT fibrils formed in the presence of individual chaperones (1:1 ratio), mirroring the initial ThT assay conditions. Strikingly, we found that Hsc70 and DnaJA2 were the only chaperones effective at reducing tau prions (Fig. 4c ). DnaJA2 was particularly effective in this platform, and it even suppressed tau prions formed from P301L and A152T mutants. Thus, these results suggest that DnaJA2 probably acts on tau during the aggregation process to lower both its aggregation and its seeding potential.
DnaJA2 is upregulated in affected neurons of MCI and AD patients. We asked whether DnaJA2 was linked to tau aggregate pathology in vivo. To test this idea, brain slices from patients with MCI or AD were labeled with antibodies for phospho-tau (AT8, green) and DnaJA2 (red). In addition, we used propidium iodide (PI) to indicate nuclei (blue) and FSB to stain amyloid (white). First, we confirmed that MCI samples had sparse tau pathology as marked by AT8 positivity ( Supplementary Fig. 6a ), whereas samples from patients with AD had greater pathology ( Supplementary  Fig. 6b ). In MCI samples, neurons positive for AT8 and/or FSB staining (Fig. 5a,b ) had strikingly increased levels of DnaJA2 compared to surrounding neurons in the same sample or nondemented controls (Fig. 5c ). Interestingly, the DnaJA2 staining does not colocalize with the AT8 or FSB signals in the soma or neurites (Fig. 5a,b ) of affected MCI neurons; rather, it was interspersed or surrounding the marked regions of pathology ( Supplementary  Fig. 6c ). Quantification of DnaJA2 levels showed increased staining for DnaJA2 in 80% of AT8-positive neurons in MCI samples (Fig. 5d ) and 31% of AT8-positive neurons in AD (Fig. 5e ). These results suggested that DnaJA2 might be a protective factor that diminishes in AD neurons. We also noted that, in AD samples, there was prominent DnaJA2 staining at sites just adjacent to neurons, which are potentially surrounding glial cells ( Supplementary Fig. 6d ).
Next, we compared the DnaJA2 results to staining with a control J protein, DnaJB4. In contrast to our findings with DnaJA2, DnaJB4 levels remained unchanged between AT8-negative and AT8-positive neurons ( Supplementary Fig. 6f ). Only one out of 18 AT8-positive neurons showed upregulation of DnaJB4 in MCI samples, and no upregulation of DnaJB4 was observed in AD samples. A dot blot against purified recombinant proteins indicated that the DnaJA2 antibody was specific among a panel of other J proteins and did not detect the closely related family member DnaJA1 ( Supplementary  Fig. 6e ). We were unable to validate a DnaJA1-specific antibody for our study.
Finally, we examined the immunostaining patterns for several other anti-tau-aggregation chaperones including Hsc70, Hsp72 and Hsp27. Hsc70 and Hsp72 staining patterns were not altered in AT8-positive neurons from MCI samples ( Supplementary Fig. 6f,h) , whereas Hsp27 was primarily observed in non-neuronal cells in nondemented controls ( Supplementary Fig. 6g ), MCI samples (data not shown) and AD samples ( Supplementary Fig. 6g ). In AD samples, Hsp27 staining was additionally observed in FSB-positive neurons. Together, these results suggest that within the larger chaperone network, DnaJA2 might be relatively specific to tau pathology in early stages of neurodegeneration. Moreover, this response might be muted or altered in later stages of disease.
Discussion
Client proteins, such as tau, encounter a network of chaperones and co-chaperones in the cell. In turn, the structural and chemical features of that client are 'interpreted' by the chaperones, and decisions about the fate of the client (fold, traffic or degrade) are made. We wanted to understand this molecular recognition process in more detail. Genetic 12,54,55 and proteomic 17, 18 studies have started to identify which chaperones associate with tau and which ones tune its levels. However, we were interested in learning which chaperones physically bind to tau and how tau variants (mutation, PTMs) impact this molecular recognition. Biochemical and biophysical approaches allowed us to broadly examine tau variants and their direct binding to candidate chaperones. On the other hand, this approach is reductionist in some important ways; for example, chaperones rarely work by themselves, and many of them operate in an ATP-rich environment with a full complement of stress responses associated signaling factors and crowding agents. None of those features are replicated in our studies. Despite this limitation, we uncovered some previously unknown relationships that could have implications for chaperone biology and tauopathies.
Forging new connections between chaperones, tau, and diseaserelated pathology. Although DnaJA2 is known to be a co-chaperone of the Hsp70s, it had not previously been linked to tau homeostasis. However, our results suggest that it could be an early marker of tau pathology. Previous transcriptome analyses of brain tissues found a moderate decrease in DnaJA2 mRNA transcripts coincident with age and AD 2 ; however, our results suggest that DnaJA2 protein levels can be highly variable even between individual neurons within the same sample. For example, we found that specific neurons with tau pathology had dramatically higher DnaJA2 levels compared to those of neighboring cells, which would probably not be clear in whole-brain transcriptome studies. Follow-up studies will be aimed at testing the hypothesis that DnaJA2 is an early protective factor that limits tau aggregation. Specifically, it seems possible that deficiencies in either its levels or its function may coincide with nucleation sites for pathology.
Other chaperones also warrant further investigation. For example, multiple studies have identified the CLU gene encoding clusterin as a significant risk factor for AD 24 . Clusterin, a secreted protein, has reported anti-aggregation activities towards Aβ , another amyloidogenic protein implicated in AD. Tau is thought to be secreted from neurons 56 , and elevated tau in the cerebrospinal fluid is a diagnostic marker of AD 57 . Thus, our findings raise the interesting possibility that clusterin has another protective function to bind and sequester extracellular tau. Another potentially interesting chaperone is the prolyl isomerase FKBP12. In AD samples, the overall expression of FKBP12 is decreased, but a strong colocalization pattern of NFTs with FKBP12 was observed 27 . There is a report that FKBP12 delays aggregation of a short tau peptide containing the PHF6 aggregation motif 58 ; however, we found no evidence of anti-aggregation activity in any of the longer tau constructs used in our study. In contrast, our findings suggest that FKBP12 might promote tau aggregation, at least for some acetylated variants.
Do disease-related mutations and PTMs in tau evade chaperone function?.
Tau pathology has been linked to point mutations, truncations and aberrant PTMs. Why do some variants, such as P301L, cause disease? We wondered whether some of these variants might 'avoid' the chaperone system, possibly contributing to an imbalance in their own homeostasis. Indeed, we observed a striking reduction in anti-aggregation activity for particular tau variations, such as P301L and D421. Of the 50 + tau mutations linked to tauopathy, P301L is the most common 59 , whereas accumulation of the D421 fragment is prevalent in patients with AD and is correlated with cognitive decline 60 . Thus, we hypothesize that some tau variants, but likely not all, lose affinity for key surveillance chaperones, such as DnaJA2. Over time, this failed recognition might contribute to increased tau levels and its deposition. It is likely that many other factors also contribute, but it is compelling to envision that a failure of surveillance chaperones is one issue.
Methods
Methods, including statements of data availability and any associated accession codes and references, are available at https://doi. org/10.1038/s41594-018-0057-1.
In vitro tau aggregation. All proteins in the aggregation assay were dialyzed overnight at 4 °C into assay buffer (Dulbecco's PBS, pH 7.4, 2 mM MgCl 2 and 1 mM DTT). Tau (10 µ M) was pre-incubated in the presence or absence of chaperones (2.5-20 µ M) for 30 min at 37 °C. ThT (Sigma) at a final concentration of 10 µ M was added, and aggregation was induced by the addition of a freshly prepared heparin sodium salt solution (Santa Cruz) at a final concentration of 44 µ g/ml. For non-induced controls, assay buffer was added in place of heparin solution. In assays using arachidonic acid as an aggregation inducer, heparin was replaced with arachidonic acid (150 µ M) in 5% ethanol, and non-induced controls contained 5% ethanol. Aggregation reactions were carried out at 37 °C with continuous shaking and monitored via ThT fluorescence (excitation, 444 nm; emission, 485 nm; cutoff, 480 nm) in a Spectramax M5 microplate reader (Molecular Devices). Readings were taken every 5 min for a minimum of 24 h. Note that for experiments with Hsp72 SBD , assays were performed at 30 °C, well below its observed protein melting point (42 °C) . Chaperones with poor solubility in standard screen conditions, as indicated in the text, were assayed in reactions with the following modifications: the tau concentration was reduced to 7.5 µ M and the aggregation reaction was carried out in 96 well plates with total volumes of 200 µ l per well.
For data processing, baseline curves of non-induced controls (three replicates) were subtracted from induced samples (three replicates). Baseline-subtracted aggregation curves were analyzed in Grace plotting program (http://plasma-gate. weizmann.ac.il/Grace/) and fit to the Goempertz function 61,62 :
where y = the fluorescence at time (t), A is the amplitude of curve, t i is the inflection point, t i -b = lag time, and b = 1/k app , where k app is the apparent elongation rate constant. Amplitude values are represented relative to 0N4R tau WT controls for each experiment to adjust for day-to-day fluctuations in absolute ThT signal intensity. Curves with final amplitude values < 15% of the internal tau-alone controls were classified as non-aggregating. For the primary aggregation screen, each experiment contained multiple reference controls including Hsc70 NBD and Hsc70 (at each concentrated tested) and 0N4R tau WT (10 µ M). The effect of each chaperone on aggregation kinetics is normalized to the values for the internal Hsc70 NBD and Hsc70 controls. Heat maps for chaperone effects on aggregation kinetics were generated in R 63 . For experiments involving chaperone addition after the lag phase period, the aggregation curve for 4 h immediately following addition was fit with linear regression to calculate the slope.
In vitro tau seeding reaction. Tau (10 µ M) was aggregated in 1.7 ml microcentrifuge tubes under conditions similar to the aggregation screen, except ThT was omitted. When indicated, 10 µ M chaperone was also present. Unfractionated aggregate mixtures were quantified by gel electrophoresis, then added at a final concentration of (30 nM tau) to seed fresh tau monomer solutions (10 µ M tau, Dulbecco's PBS, pH 7.4, 2 mM MgCl 2 , 1 mM DTT, 10 µ M ThT, 44 µ g/ml heparin). The aggregation reaction was monitored and analyzed as described in 'In vitro tau aggregation' .
Tau peptide microarray. Experimental design and procedure for the tau peptide microarray has been described previously 17 . Briefly, the microarrays were printed on single microscope slides in triplicate, with peptides covalently immobilized at the N terminus (Jenrin Peptide Technologies, Berlin, Germany). Peptide binding was tested per manufacturer's protocol using 10 μ M of His6 × -tagged protein in binding buffer (25 mM HEPES, pH 7.2, 150 mM NaCl, 20 mM KCl, 5 mM MgCl 2 , 0.01% Tween20). Binding was detected with a 1:1,000 dilution of HiLyte555 anti-His6× antibody (AS-61250-H488, Anaspec, Fremont, CA) in TBS-T with 1% BSA (Sigma), and microarrays were screened using a GenePix 4100A Microarray Scanner (Molecular Devices, Sunnyvale, CA) at an excitation wavelength of 532 nm. Empty spots were used as negative controls. Binding was defined as > 2 consecutive peptides with fluorescence signals greater than one standard deviation above the mean in replicate experiments. Peptides that bound to the anti-His6× antibody alone or to an Hsc70 construct lacking its SBD (Hsc70 NBD ) were identified as false positives and excluded from further analysis. Positive sites were restricted to those composed of two or more consecutive binding peptides. The one exception was peptide (aa 5-29), which was included because the peptide preceding it was a false positive. Tau cellular seeding assay. The HEK293 cell line stably expressing the microtubule-binding repeat region of tau fused to YFP (clone 1) was kindly provided by M. Diamond 53 . The cell line stock tested negative for mycoplasma. Cells were plated at a density of 2,000 cells/well in 384-well clear black plates (Greiner Bio-One) and immediately treated with unfractionated tau fibril preparations (0-1 µ g tau/well). For experiments in which Lipofectamine 2000 (Thermo Fisher Scientific) was used to introduce fibrils, a ratio of 1 µ g tau protein/0.3 µ L Lipofectamine 2000 was used. Following a 48-h treatment, nuclei were stained in live cells with 0.012 µ g/well of Hoescht 33342 (Thermo Fisher Scientific) for 1 h. Images for DAPI and FITC channels from three regions per well were captured using an InCell 6000 (GE HealthCare). The images were processed using InCell Developer software (GE HealthCare) with an algorithm developed to identify live cells with intracellular aggregates larger than 0.89 µ m 2 . Greater than 600 cells per well, assayed in triplicate, was analyzed in three independent experiments.
Fibril sedimentation. Tau aggregation samples were centrifuged at 100,000g for 1 h at 4 °C. Supernatants were collected, and pellets were suspended in aggregation assay buffer overnight at room temperature with shaking. SDS sample buffer Human tissue samples. Seven formalin-fixed brain tissue samples were obtained from neuropathologically confirmed cases of Alzheimer's disease (Braak stage V-VI), mild cognitive impairment (Braak stage II), or non-demented aged control. Medial frontal cortex and inferior temporal cortex regions were utilized for this study. Tissue was obtained from the University of California San Francisco Neurodegenerative Disease Brain Bank. All procedures for animal use were approved by the UCSF Institutional Review Board's Human Research Protection Program.
Immunohistochemistry and confocal imaging. Formalin-fixed samples were embedded in paraffin using standard procedures. Sections (8 µ m) were cut, photobleached using a multispectral LED lamp, deparaffinized, then processed for immunohistochemistry. Sections stained with antibodies were pretreated by incubation in heated 0.01 M sodium citrate buffer as an epitope-retrieval step. Following blocking with 10% normal goat serum, sections were incubated with primary antibody overnight at 4 °C (see Supplementary Table 4 for antibody specifications). Primary antibody detection was performed using goat secondary antibodies with conjugated AlexaFluor488 or AlexaFluor647 (A-21245, Life Technologies). All immunohistochemistry-stained sections were subsequently stained with 2.5 µ M fluorostyrylbenzene (FSB; Congo red derivative) (Santa Cruz) in 1× PBS and washed with propidium iodide (Sigma) before mounting. Samples were visualized using a 40× water-immersion lens (1.1 NA) or 63× oilimmersion (1.4 NA) in sequential scan mode on a Leica SP8 confocal microscope equipped with HyD detectors. 8-bit image z stacks (1-µ m steps) were collected at 1,024 × 1,024 or 2,048 × 2,048 pixel resolution. Images were processed using NIH ImageJ.
Isothermal calorimetry (ITC). Chaperones were dialyzed into ITC buffer overnight (40 mM HEPES, pH7.4, 150 mM NaCl). Protein concentrations were determined via BCA assay (Pierce). The experiment was carried out at 25 °C on a MicroCal VP-ITC where heparin at 200 µ M or 1 mM (based on an average MW of 9,500) was titrated into a 100 µ M cell solution of Hsc70 or DnaJA2. Calorimetric parameters were calculated using Origin 7.0 software and fit with a one-site binding model.
Dot blot.
Purified recombinant chaperones (1.5 µ g or 0.75 µ g total) were spotted on nitrocellulose, stained with Ponceau S to verify transfer, and then processed by immunoblot. The membrane was blocked in 4% milk solution then incubated with DnaJA2 antibody (1:20,000) at 4 °C, overnight. The membrane was incubated with goat anti-mouse HRP (1:40,000, Cell Signaling Technology) for 45 min prior to chemiluminescence signal detection with ECL Select (Amersham) by a Chemidoc Touch gel imaging system (Bio-Rad).
Reporting Summary. Further information on experimental design is available in the Nature Research Reporting Summary linked to this article.
Data availability.
Mutations and post-translational modifications in tau mimicked in this study are described in refs [64] [65] [66] [67] [68] and listed in Supplementary  Table 1 . Purification of individual chaperones is described in refs [69] [70] [71] [72] [73] [74] [75] [76] [77] [78] [79] and listed in Supplementary Table 3 . The datasets generated and analyzed in the current study are available from the corresponding author upon reasonable request.
